Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape

Ruben Niesvizky, MD
Published: Monday, May 08, 2017



Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

There has been a large evolution in the management of these patients, he explains. Physicians have tried to change the treatment algorithms to achieve the best responses possible in all patient populations, including those who are elderly. This has helped with revised criteria.

With this, physicians will be able to begin doing early intervention with agents such as lenalidomide (Revlimid) and dexamethasone, as well as more aggressive induction consolidation and maintenance regimens.


Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

There has been a large evolution in the management of these patients, he explains. Physicians have tried to change the treatment algorithms to achieve the best responses possible in all patient populations, including those who are elderly. This has helped with revised criteria.

With this, physicians will be able to begin doing early intervention with agents such as lenalidomide (Revlimid) and dexamethasone, as well as more aggressive induction consolidation and maintenance regimens.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x